A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

About the speaker

Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

7 More presentations in this session

Presentation thumbnail

Discussant - Risk factors and prevention

Presentation thumbnail

Inclisiran: a breakthrough in LDL-C reduction for indian ASCVD patients

Doctor R. Yalamanchi (Chennai, IN)

Presentation thumbnail

Adherence to statin therapy after inclisiran start, insights from the the DAMAGE registry

Associate Professor F. Guerra (Ancona, IT)

Presentation thumbnail

Short-term impact of e-cigarrette without nicotine in cardiovascular system in comparison to e-cigarette without nicotine and combustile cigarette

Doctor P. Sobieraj (Warsaw, PL)

Presentation thumbnail

Disparities in importance physicians place on anti-obesity medications to help prevent cardiovascular comorbidities across the US and Germany

Doctor M. Tan (London, GB)

Access the full session

Session thumbnail

New perspectives in cardiology (3) - Risk factors and prevention

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Session

Changing face of lipid-lowering therapy

Congress Presentation

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry

Congress Session

Fine-tuning post-acute coronary syndrome cardio protection: the case for early and aggressive lipid-lowering

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources